Johnson and Johnson (JNJ)

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained...

Form 11-K - Annual report of employee stock purchase, savings and similar plans

Form 11-K - Annual report of employee stock purchase, savings and similar plans

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Investment includes new advanced manufacturing and packaging technologies and a new state-of-the-art...

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Johnson & Johnson Reports Strong Late-Stage Results for Rare Blood Disorder Therapy (JNJ)

Johnson & Johnson (NYSE:JNJ) has announced positive findings from its Phase 2/3 ENERGY clinical trial, with IMAAVY (nipocalimab-aahu...

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Expanded U.S. availability paired with new patient lifestyle quiz encourages informed decision-making ahead of cataract surgery. Cataracts are...

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune...

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers Acquisition adds a proprietary degrader...

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus...